Sabine Huke
Last active: 5/27/2014

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization. Sivakumaran V, Stanley BA, Tocchetti CG, Ballin JD, Caceres V, Zhou L, Keceli G, Rainer PP, Lee DI, Huke S, Ziolo MT, Kranias EG, Toscano JP, Wilson GM, O'Rourke B, Kass DA, Mahaney JE, Paolocci N (2013) Antioxid Redox Signal 19(11): 1185-97
    › Primary publication · 23919584 (PubMed) · PMC3785857 (PubMed Central)
  2. Familial hypertrophic cardiomyopathy: is the Frank-Starling law kaput? Huke S, Knollmann BC (2013) Circ Res 112(11): 1409-11
    › Primary publication · 23704214 (PubMed) · PMC3767756 (PubMed Central)
  3. Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments. Huke S, Venkataraman R, Faggioni M, Bennuri S, Hwang HS, Baudenbacher F, Knollmann BC (2013) Circ Res 112(10): 1334-44
    › Primary publication · 23532597 (PubMed) · PMC3850761 (PubMed Central)
  4. Visualizing regional myocardial blood flow in the mouse. Krueger MA, Huke SS, Glenny RW (2013) Circ Res 112(9): e88-97
    › Primary publication · 23513055 (PubMed)
  5. Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Schober T, Huke S, Venkataraman R, Gryshchenko O, Kryshtal D, Hwang HS, Baudenbacher FJ, Knollmann BC (2012) Circ Res 111(2): 170-9
    › Primary publication · 22647877 (PubMed) · PMC3393041 (PubMed Central)
  6. Oxidized CaMKII: a "heart stopper" for the sinus node? Huke S, Knollmann BC (2011) J Clin Invest 121(8): 2975-7
    › Primary publication · 21785211 (PubMed) · PMC3148748 (PubMed Central)
  7. SR-targeted CaMKII inhibition improves SR Ca²+ handling, but accelerates cardiac remodeling in mice overexpressing CaMKIIδC. Huke S, Desantiago J, Kaetzel MA, Mishra S, Brown JH, Dedman JR, Bers DM (2011) J Mol Cell Cardiol 50(1): 230-8
    › Primary publication · 20971119 (PubMed) · PMC3018844 (PubMed Central)
  8. Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks. Guo T, Cornea RL, Huke S, Camors E, Yang Y, Picht E, Fruen BR, Bers DM (2010) Circ Res 106(11): 1743-52
    › Primary publication · 20431056 (PubMed) · PMC2895429 (PubMed Central)
  9. Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility. Huke S, Knollmann BC (2010) J Mol Cell Cardiol 48(5): 824-33
    › Primary publication · 20097204 (PubMed) · PMC2854218 (PubMed Central)
  10. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, Piston DW, Huke S, Knollmann BC (2010) J Mol Cell Cardiol 48(2): 293-301
    › Primary publication · 19835880 (PubMed) · PMC2813417 (PubMed Central)
  11. Ablation of triadin causes loss of cardiac Ca2+ release units, impaired excitation-contraction coupling, and cardiac arrhythmias. Chopra N, Yang T, Asghari P, Moore ED, Huke S, Akin B, Cattolica RA, Perez CF, Hlaing T, Knollmann-Ritschel BE, Jones LR, Pessah IN, Allen PD, Franzini-Armstrong C, Knollmann BC (2009) Proc Natl Acad Sci U S A 106(18): 7636-41
    › Primary publication · 19383796 (PubMed) · PMC2678594 (PubMed Central)
  12. Ryanodine receptor phosphorylation at Serine 2030, 2808 and 2814 in rat cardiomyocytes. Huke S, Bers DM (2008) Biochem Biophys Res Commun 376(1): 80-5
    › Primary publication · 18755143 (PubMed) · PMC2581610 (PubMed Central)
  13. IP3 receptor-dependent Ca2+ release modulates excitation-contraction coupling in rabbit ventricular myocytes. Domeier TL, Zima AV, Maxwell JT, Huke S, Mignery GA, Blatter LA (2008) Am J Physiol Heart Circ Physiol 294(2): H596-604
    › Primary publication · 18055509 (PubMed)
  14. Temporal dissociation of frequency-dependent acceleration of relaxation and protein phosphorylation by CaMKII. Huke S, Bers DM (2007) J Mol Cell Cardiol 42(3): 590-9
    › Primary publication · 17239900 (PubMed) · PMC1857340 (PubMed Central)
  15. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Tocchetti CG, Wang W, Froehlich JP, Huke S, Aon MA, Wilson GM, Di Benedetto G, O'Rourke B, Gao WD, Wink DA, Toscano JP, Zaccolo M, Bers DM, Valdivia HH, Cheng H, Kass DA, Paolocci N (2007) Circ Res 100(1): 96-104
    › Primary publication · 17138943 (PubMed) · PMC2769513 (PubMed Central)
  16. CaMKII inhibition targeted to the sarcoplasmic reticulum inhibits frequency-dependent acceleration of relaxation and Ca2+ current facilitation. Picht E, DeSantiago J, Huke S, Kaetzel MA, Dedman JR, Bers DM (2007) J Mol Cell Cardiol 42(1): 196-205
    › Primary publication · 17052727 (PubMed) · PMC1828135 (PubMed Central)
  17. Phosphorylation-status of phospholamban and calsequestrin modifies their affinity towards commonly used antibodies. Huke S, Periasamy M (2004) J Mol Cell Cardiol 37(3): 795-9
    › Primary publication · 15350852 (PubMed)
  18. Altered force-frequency response in non-failing hearts with decreased SERCA pump-level. Huke S, Liu LH, Biniakiewicz D, Abraham WT, Periasamy M (2003) Cardiovasc Res 59(3): 668-77
    › Primary publication · 14499868 (PubMed)
  19. Altered dose response to beta-agonists in SERCA1a-expressing hearts ex vivo and in vivo. Huke S, Prasad V, Nieman ML, Nattamai KJ, Grupp IL, Lorenz JN, Periasamy M (2002) Am J Physiol Heart Circ Physiol 283(3): H958-65
    › Primary publication · 12181124 (PubMed)
  20. Loss of SM-B myosin affects muscle shortening velocity and maximal force development. Babu GJ, Loukianov E, Loukianova T, Pyne GJ, Huke S, Osol G, Low RB, Paul RJ, Periasamy M (2001) Nat Cell Biol 3(11): 1025-9
    › Primary publication · 11715025 (PubMed)
  21. SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. Periasamy M, Huke S (2001) J Mol Cell Cardiol 33(6): 1053-63
    › Primary publication · 11444913 (PubMed)
  22. Role of protein phosphatases in regulation of cardiac inotropy and relaxation. Bokník P, Khorchidi S, Bodor GS, Huke S, Knapp J, Linck B, Lüss H, Müller FU, Schmitz W, Neumann J (2001) Am J Physiol Heart Circ Physiol 280(2): H786-94
    › Primary publication · 11158978 (PubMed)
  23. Functional properties of transgenic mouse hearts overexpressing both calsequestrin and the Na(+)-Ca(2+) exchanger. Linck B, Bokník P, Huke S, Kirchhefer U, Knapp J, Lüss H, Müller FU, Neumann J, Tanriseven Z, Vahlensieck U, Baba HA, Jones LR, Philipson KD, Schmitz W (2000) J Pharmacol Exp Ther 294(2): 648-57
    › Primary publication · 10900244 (PubMed)
  24. On the cardiac contractile, electrophysiological and biochemical effects of endothall, a protein phosphatase inhibitor. Bokník P, Vahlensieck U, Huke S, Knapp J, Linck B, Lüss H, Müller FU, Neumann J, Schmitz W (2000) Pharmacology 61(1): 43-50
    › Primary publication · 10895080 (PubMed)
  25. On the contractile function of protein phosphatases in isolated human coronary arteries. Knapp J, Bokník P, Deng MC, Huke S, Lüss I, Klein-Wiele O, Linck B, Lüss H, Müller FU, Nacke P, Scheld HH, Schmitz W, Vahlensieck U, Neumann J (1999) Naunyn Schmiedebergs Arch Pharmacol 360(4): 464-72
    › Primary publication · 10551284 (PubMed)
  26. The protein phosphatase inhibitor cantharidin alters vascular endothelial cell permeability. Knapp J, Bokník P, Lüss I, Huke S, Linck B, Lüss H, Müller FU, Müller T, Nacke P, Noll T, Piper HM, Schmitz W, Vahlensieck U, Neumann J (1999) J Pharmacol Exp Ther 289(3): 1480-6
    › Primary publication · 10336542 (PubMed)
  27. Inotropic effects of diadenosine tetraphosphate (AP4A) in human and animal cardiac preparations. Vahlensieck U, Bokník P, Gombosová I, Huke S, Knapp J, Linck B, Lüss H, Müller FU, Neumann J, Deng MC, Scheld HH, Jankowski H, Schlüter H, Zidek W, Zimmermann N, Schmitz W (1999) J Pharmacol Exp Ther 288(2): 805-13
    › Primary publication · 9918592 (PubMed)
  28. Contractility and inhibition of protein phosphatases by cantharidin. Knapp J, Bokník P, Huke S, Gombosová I, Linck B, Lüss H, Müller FU, Müller T, Nacke P, Schmitz W, Vahlensieck U, Neumann J (1998) Gen Pharmacol 31(5): 729-33
    › Primary publication · 9809469 (PubMed)
  29. The mechanism of action of cantharidin in smooth muscle. Knapp J, Bokník P, Huke S, Lüss H, Müller FU, Müller T, Nacke P, Schmitz W, Vahlensieck U, Neumann J (1998) Br J Pharmacol 123(5): 911-9
    › Primary publication · 9535020 (PubMed) · PMC1565226 (PubMed Central)